Clinical study of CT-guided radiofrequency ablation plus intratumoral chemotherapy for patients with stage Ⅲ non-small cell lung cancer / 国际肿瘤学杂志
Journal of International Oncology
; (12): 73-76, 2018.
Article
en Zh
| WPRIM
| ID: wpr-693447
Biblioteca responsable:
WPRO
ABSTRACT
Objective To explore the clinical efficacy and safety of CT-guided radiofrequency ablation plus intratumoral chemotherapy in patients with stage Ⅲ non-small cell lung cancer (NSCLC).Methods From February 2014 to May 2015,38 patients with stage Ⅲ NSCLC who did not receive systematic chemotherapy due to advanced age were selected in our hospital.The patients were divided into experimental group (n =19) and control group (n =19) by stratified random method.The patients in experimental group received CT-guided radiofrequency ablation plus Lobaplatin intratumoral chemotherapy,and the patients in control group only received CT-guided radiofrequency ablation.The adverse events,Karnofsky performance system (KPS) scores,1-year overall survival rates and short-term curative effects of patients in the two groups were observed.Results All 38 patients completed the course of therapy successfully.The 3-month response rates and 6-month response rates in experimental group and control group were 89.5% vs.63.2% and 78.9% vs.52.6%,with no significant differences (P =0.124;P =0.170).The KPS score improvement rates were 42.1% (8/19) and 31.6% (6/19) in experimental group and control group,the KPS score stable rates were 52.6% (10/19) and 52.6% (10/19) in the two groups,and the KPS score deterioration rates were 5.3% (1/19) and 15.8% (3/19) in the two groups,with no significant differences (P =0.737;P =1.000;P =0.290).The 1-year survival rate of patients in experimental group was higher than that in control group (89.5% vs.73.7%),with a significant difference (x2 =5.573,P =0.034).The rates of less than or equal to grade 3 pain (31.6% vs.42.1%),low fever (21.1% vs.26.3%),aerothorax (31.6% vs.42.1%),gastrointestinal reaction (15.8% vs.31.6%) and bone marrow depression (5.3% vs.15.8%) in experimental group were lower than those in control group,but the differences were not statistically significant (P =0.501;P =0.703;P =0.501;P =0.252;P =0.290).Conclusion CT-gnided radiofrequency ablation plus intratumoral chemotherapy for stage Ⅲ NSCLC can improve short-term survival rate,and it does not increase the adverse reaction.While,the long-term overall survival rate has yet to be followed up.
Texto completo:
1
Índice:
WPRIM
Idioma:
Zh
Revista:
Journal of International Oncology
Año:
2018
Tipo del documento:
Article